With the development of prostate cancer detection and management, patients with prostate cancer at an early stage exhibit a 99% ten-year overall survival (OS) rate (16), whereas more than half of patients undergo biochemical recurrence (BCR) characterized by elevated prostate-specific antigen (PSA) levels after radical therapy (17, 18). The gene discussed is KLK3; the disease is prostate cancer.